ALPINE Trial

ALPINE (NCT03734016) is a global, Phase 3, randomized trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).